ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia



    - Update on Clinical Developments

    MONTREAL, March 6 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI)
("ProMetic") announces favorable top-line findings from the third cohort in
its Phase II trial with PBI-1402 in patients with chemotherapy-induced anemia
("CIA"). Analysis of the compiled data from a total of 18 patients showed an
overall statistically significant increase of the mean hematocrit values at
weeks 4, 6 and 8, and of the hemoglobin values at week 8. At week 8, p values
were 0.02 for hematocrit and hemoglobin. More detailed results from the study
have been submitted to the European Hematology Association for presentation at
their June 2008 meeting in Copenhagen.
    "These results are very encouraging and continue to demonstrate the
efficacy and safety profile of PBI-1402, a non-EPO (erythropoietin) treatment
for CIA," states Mr. Pierre Laurin, President and Chief Executive Officer of
ProMetic Life Sciences Inc. "We are excited about the prospects for PBI-1402
for the treatment of anemia in oncology since, unlike EPO, PBI-1402
demonstrated some anticancer activity in animal models. We look forward to
sharing more detailed clinical trial results."
    Other PBI-1402 development highlights include the extension of the
enrollment for the PBI-1402 CIA trial to include an additional 12 patients
receiving the lowest trial dose. Data from these additional patients are
expected by June 2008.
    In addition, a new Phase II study in patients with anemia resulting from
chronic kidney disease has been scheduled. This multi-center study will be
placebo controlled and will examine the effect of PBI-1402 on anemia, as well
as several other clinical parameters. Conclusive results obtained recently in
animal models have confirmed the erythropoiesis activity of PBI-1402 even when
there is little or no endogenous EPO produced by the kidney.

    About PBI-1402

    PBI-1402 is an orally active compound being developed to treat different
types of anemia, such as CIA. PBI-1402 has a distinct mechanism of action and
does not act through EPO receptor. ProMetic has recently expanded its clinical
program for PBI-1402 into the treatment of anemia in patients with
myelodysplastic syndrome ("MDS"), a condition often referred to as
"pre-leukemia".

    About ProMetic Life Sciences Inc.

    ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical
company specialized in the research, development, manufacture and marketing of
a variety of commercial applications derived from its proprietary Mimetic
Ligand (TM) enabling technology. This technology is used in large-scale
purification of biologics and the elimination of pathogens. ProMetic is also
active in therapeutic drug development with the mission to bring to market
effective, innovative, lower cost, less toxic products for the treatment of
hematology and cancer. Its drug discovery platform is focused on replacing
complex, expensive proteins with synthetic "drug-like" protein mimetics.
Headquartered in Montréal (Canada), ProMetic has R&D facilities in the U.K.,
U.S. and Canada, manufacturing facilities in the U.K. and business development
activities in the U.S., Europe, Asia and the Middle-East.

    Forward Looking Statements

    This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks
affect our business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited to,
ProMetic's ability to develop, manufacture, and successfully commercialize
value-added pharmaceutical products, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of ProMetic to take advantage of business opportunities
in the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or results to
materially differ from our current expectations on page 21 of ProMetic's
Annual Information Form for the year ended December 31, 2006, under the
heading "Risk Factors". As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a
result of future events or for any other reason, unless required by applicable
securities laws and regulations.




For further information:

For further information: Company Inquiries: Pierre Laurin, President and
CEO, ProMetic Life Sciences Inc., (514) 341-2115, p.laurin@prometic.com;
Dominic Sicotte, Echoes Financial Network Inc., (514) 842-9551,
dsicotte@echoesfinancial.com; Anne Leduc, Manager, Investor Relations and
Communications, ProMetic Life Sciences Inc., (514) 341-2115,
a.leduc@prometic.com; Investor Relations: Bruce Voss, Lippert/Heilshorn &
Associates, (310) 691-7100, BVoss@lhai.com; Kim Golodetz, Lippert/Heilshorn &
Associates, (212) 838-3777, KGolodetz@lhai.com; Media Relations: Jules
Abraham, Lippert/Heilshorn & Associates, (212) 838-3777, JAbraham@lhai.com

Organization Profile

PROMETIC LIFE SCIENCES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890